China-Made Human Bird-Flu Vaccine Ready for Clinical Test
Posted on: Thursday, 10 November 2005, 09:00 CST
Text of report in English by official Chinese news agency Xinhua (New China News Agency)
Beijing, 10 November: China's self-made human avian influenza vaccine is waiting for the approval of a clinical test, said a health official here Thursday [10 November].
Preclinical experiments of the vaccine, which started in May 2004, have ended. A clinical test will be carried out as soon as the State Food and Drug Administration approves it, said Wang Yu, director of the Chinese Centre for Disease Control and Prevention.
The vaccine for human avian influenza was jointly developed by the centre and a Chinese drug company. Clinical tests will further prove its safety and effectiveness, he said at the first China- Thailand-Vietnam workshop on prevention and control of human avian influenza.
Officials and experts from the Chinese Ministry of Health, the disease control and prevention centre, the Ministry of Public Health of Thailand, the National Institute of Hygiene and Epidemiology of Vietnam, Hong Kong and Macao are sharing information and techniques to curb human avian influenza on Thursday and Friday.
A cooperative mechanism is to be set up by the three countries soon and the workshop will be held every one or two months.
Source: BBC Monitoring Asia Pacific
Related Articles
- Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
- Sinovac Attended 3rd WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials
- Sinovac Announces Its Clinical Trial Results of a Pandemic Influenza (H5N1) Vaccine Are Published By The Lancet
- Vaccine for Hepatitis C in Clinical Trial
- China's Human Trial of AIDS Vaccine Proceeding Smoothly
- No Human Cases of Avian Flu Health Minister
- Skystar Bio-Pharmaceutical Developing Avian Influenza (H5N1) Vaccine for Humans and Animals
- Chinese Government to Adopt Regulation on HIV/AIDS Prevention, Control
- Chiron Delivers FLUVIRIN(R) Influenza Virus Vaccine to U.S. Customers
- Chinese Anti-Cancer Vaccine Approved for Clinical Research
User Comments (0)

RSS Feeds